SB-271046 is one of the first selective 5-HT6 receptor antagonists to be discovered. SB-271046 was found to be potent and selective in vitro and had good oral bioavailability in vivo, but had poor penetration across the blood–brain barrier. SB-271046 was found to increase levels of the excitatory amino acid neurotransmitters glutamate and aspartate, as well as dopamine and noradrenaline in the frontal cortex and hippocampus of rats, and 5-HT6 antagonists have been shown to produce nootropic effects in a variety of animal studies. Suggested applications of these drugs include treatment of schizophrenia and other psychiatric disorders.
5-HT Receptor Antagonists Related Products:
Prucalopride; Prucalopride Succinate; Agomelatine; Blonanserin; Azasetron HCl; Dolasetron mesylate; Palonosetron hydrochloride; Lurasidone; Intepirdine; Mirtazapine